FMP

FMP

Enter

KOD - Kodiak Sciences Inc.

Financial Summary of Kodiak Sciences Inc.(KOD), Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commerci

photo-url-https://financialmodelingprep.com/image-stock/KOD.png

Kodiak Sciences Inc.

KOD

NASDAQ

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

2.78 USD

-0.04 (-1.44%)

About

ceo

Dr. Victor Perlroth M.D.

sector

Healthcare

industry

Biotechnology

website

https://kodiak.com

exchange

NASDAQ

Description

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry ...

CIK

0001468748

ISIN

US50015M1099

CUSIP

50015M109

Address

1200 Page Mill Road

Phone

650 281 0850

Country

US

Employee

107

IPO Date

Oct 4, 2018

Summary

CIK

0001468748

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

50015M109

ISIN

US50015M1099

Country

US

Price

2.78

Beta

2.42

Volume Avg.

666.23k

Market Cap

146.05M

Shares

-

52-Week

1.37-9.67

DCF

1.98

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.63

P/B

-

Website

https://kodiak.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest KOD News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep